Computational Biology for Drug Development

MiraOmics is a computational biology and bioinformatics team working with pharma and biotech researchers. We build MiraTyper and use it to analyze H&E, single-cell, spatial, and protein data, helping teams design cohorts, investigate response, and understand tissue biology.

Leadership

Eugene Bolotin

Eugene Bolotin

Co-Founder & CEO

Eugene guides MiraOmics’ scientific strategy, drawing on experience in biomarker discovery and patient stratification. He previously led bioinformatics at Santa Ana Bio and held leadership roles at Kite Pharma, Cell Design Labs, and Illumina. He earned his doctorate in genetics, genomics, and bioinformatics at UC Riverside.

RJ Honicky

RJ Honicky

Co-Founder & CTO

RJ builds the engineering and data science capabilities behind MiraOmics. At Tarana Wireless, he directed engineering teams working on AI/ML, data science, and manufacturing test systems, following technical and research roles at Nokia Research and Network Appliance. He earned his computer science doctorate at UC Berkeley.

Serge Bery

Serge Bery

Chief Information Security Officer

Serge brings experience in cybersecurity, cloud services, and technology risk to MiraOmics. He previously headed security at Hewlett-Packard and Micro Focus, with earlier leadership roles at Smarsh, Microsoft, Aircell, and Allscripts. His background spans engineering, security governance, and business resilience, and he holds CISM and CISA certifications.

Built by People Who Ship

From early discovery through regulatory submission, on programs where resolving cell identity and state decided the outcome.

Experience

A Multidisciplinary Team

Our computational biology, bioinformatics, engineering, and curation teams work with a network of compute infrastructure, biosample handling, and clinical sample providers.

Regulatory

IND and FDA Submissions

Hands-on contribution to regulatory submissions, and the reproducibility and documentation discipline those demand.

Platforms

Single-Cell, Spatial and Imaging

Delivered analysis across scRNA-seq and high-plex spatial platforms, and the H&E that every trial already collects.

Start with One Asset and One Decision

A focused pilot demonstrates value on a single program, against success metrics agreed up front.